LT2646031T - Vaisto biologinio prieinamumo padidinimas naltreksono terapijos atveju - Google Patents

Vaisto biologinio prieinamumo padidinimas naltreksono terapijos atveju

Info

Publication number: LT2646031T
Authority: LT; Lithuania
Prior art keywords: drug bioavailability; increasing drug; naltrexone therapy; naltrexone; therapy
Prior art date: 2010-12-03

Application number

LTEP11845186.3T

Other languages

English (en)

Inventor

Shawn Flanagan

Eduardo Dunayevich

Original Assignee

Orexigen Therapeutics, Inc.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2010-12-03

Filing date

2011-12-02

Publication date

2017-06-26

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46172304&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LT2646031(T) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2011-12-02 Application filed by Orexigen Therapeutics, Inc. filed Critical Orexigen Therapeutics, Inc.

2017-06-26 Publication of LT2646031T publication Critical patent/LT2646031T/lt

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M21/00—Other devices or methods to cause a change in the state of consciousness; Devices for producing or ending sleep by mechanical, optical, or acoustical means, e.g. for hypnosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Emergency Medicine (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Hematology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Diabetes (AREA)
Obesity (AREA)
Child & Adolescent Psychology (AREA)
Physics & Mathematics (AREA)
Acoustics & Sound (AREA)
Psychology (AREA)
Anesthesiology (AREA)
Biomedical Technology (AREA)
Heart & Thoracic Surgery (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)
Coloring Foods And Improving Nutritive Qualities (AREA)

LTEP11845186.3T 2010-12-03 2011-12-02 Vaisto biologinio prieinamumo padidinimas naltreksono terapijos atveju LT2646031T (lt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US41939510P	2010-12-03	2010-12-03
PCT/US2011/063177 WO2012075459A1 (en)	2010-12-03	2011-12-02	Increasing drug bioavailability in naltrexone therapy

Publications (1)

Publication Number	Publication Date
LT2646031T true LT2646031T (lt)	2017-06-26

Family

ID=46172304

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
LTEP23209711.3T LT4349369T (lt)	2010-12-03	2011-12-02	Vaisto biologinio įsisavinamumo pagerinimas taikant naltreksono terapiją
LTEP21152314.7T LT3884947T (lt)	2010-12-03	2011-12-02	Augantis vaisto įsisavinimas taikant naltreksono terapiją
LTEP17156985.8T LT3222280T (lt)	2010-12-03	2011-12-02	Vaistų biologinio prieinamumo padidinimas naltreksono terapijoje
LTEP11845186.3T LT2646031T (lt)	2010-12-03	2011-12-02	Vaisto biologinio prieinamumo padidinimas naltreksono terapijos atveju

Family Applications Before (3)

Application Number	Title	Priority Date	Filing Date
LTEP23209711.3T LT4349369T (lt)	2010-12-03	2011-12-02	Vaisto biologinio įsisavinamumo pagerinimas taikant naltreksono terapiją
LTEP21152314.7T LT3884947T (lt)	2010-12-03	2011-12-02	Augantis vaisto įsisavinimas taikant naltreksono terapiją
LTEP17156985.8T LT3222280T (lt)	2010-12-03	2011-12-02	Vaistų biologinio prieinamumo padidinimas naltreksono terapijoje

Country Status (27)

Country	Link
US (1)	US20130245056A1 (lt)
EP (4)	EP4349369B1 (lt)
JP (5)	JP6008866B2 (lt)
KR (5)	KR20140035320A (lt)
CN (1)	CN103313711A (lt)
AR (2)	AR093182A1 (lt)
AU (2)	AU2011336304B2 (lt)
BR (1)	BR112013013390A2 (lt)
CA (2)	CA2819262C (lt)
CL (1)	CL2013001564A1 (lt)
CY (2)	CY1118968T1 (lt)
DK (4)	DK3222280T3 (lt)
ES (2)	ES2625527T3 (lt)
FI (2)	FI4349369T3 (lt)
HR (4)	HRP20251576T1 (lt)
HU (3)	HUE065852T2 (lt)
IL (3)	IL226504B (lt)
LT (4)	LT4349369T (lt)
MX (2)	MX356801B (lt)
PL (3)	PL2646031T3 (lt)
PT (4)	PT2646031T (lt)
RS (3)	RS62149B1 (lt)
RU (1)	RU2640561C2 (lt)
SI (3)	SI3222280T1 (lt)
SM (4)	SMT202500474T1 (lt)
TW (1)	TWI618536B (lt)
WO (1)	WO2012075459A1 (lt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK2316456T3 (en)	2003-04-29	2017-09-11	Orexigen Therapeutics Inc	Compositions for affecting weight loss comprising an opioid antagonist and bupropion
JP5180092B2 (ja)	2005-11-22	2013-04-10	オレキシジェン・セラピューティクス・インコーポレーテッド	インスリン感受性を増すための組成物および方法
WO2007089318A2 (en) *	2005-11-23	2007-08-09	Orexigen Therapeutics, Inc.	Compositions and methods for reducing food cravings
CA2725930A1 (en)	2008-05-30	2009-12-30	Orexigen Therapeutics, Inc.	Methods for treating visceral fat conditions
ES2762113T3 (es)	2010-01-11	2020-05-22	Nalpropion Pharmaceuticals Inc	Métodos de proporcionar terapia de pérdida de peso en pacientes con depresión mayor
PT2646031T (pt) *	2010-12-03	2017-05-25	Orexigen Therapeutics Inc	Aumento da biodisponibilidade farmacológica numa terapêutica com naltrexona
KR20210012056A (ko)	2012-06-06	2021-02-02	오렉시젠 세러퓨틱스 인크.	과체중 및 비만의 치료 방법
US20180015042A1 (en) *	2015-02-07	2018-01-18	Intas Pharmaceuticals Ltd.	Pharmaceutical composition for the treatment of obesity
EP3600433B1 (en) *	2017-03-28	2021-05-05	LDN Pharma Limited	An agent that increases the expresssion of the bcl2-associated agonist of cell death for the treatment of cancer
EP3482751A1 (en) *	2017-11-14	2019-05-15	LDN Pharma Limited	Cancer treatment
US12303604B1 (en)	2024-10-16	2025-05-20	Currax Pharmaceuticals Llc	Pharmaceutical formulations comprising naltrexone and/or bupropion

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE10129265A1 (de) *	2001-06-18	2003-01-02	Hf Arzneimittelforsch Gmbh	Wirkstoff-Kombination zur medikamentösen Sucht- oder Rauschmitteltherapie
US6972291B2 (en) *	2002-07-02	2005-12-06	Bernstein Richard K	Method for reducing food intake
EP1772147A2 (en) *	2003-03-17	2007-04-11	Japan Tobacco, Inc.	Method for increasing the oral bioavailability of S-[2-([[1-(2-ethylbutyl)cyclohexyl]carbonyl]amino)phenyl]-2-methylpropanethioate
DK2316456T3 (en)	2003-04-29	2017-09-11	Orexigen Therapeutics Inc	Compositions for affecting weight loss comprising an opioid antagonist and bupropion
BRPI0613911A2 (pt)	2005-07-27	2011-02-22	Orexigen Therapeutics Inc	composições para afetar a perda de peso
US8921344B2 (en) *	2006-11-03	2014-12-30	Salix Pharmaceuticals, Inc.	Formulations and uses of 2-hydroxy-5-phenylazobenzoic acid derivatives
JP5180092B2 (ja)	2005-11-22	2013-04-10	オレキシジェン・セラピューティクス・インコーポレーテッド	インスリン感受性を増すための組成物および方法
WO2007089318A2 (en) *	2005-11-23	2007-08-09	Orexigen Therapeutics, Inc.	Compositions and methods for reducing food cravings
AR058239A1 (es)	2005-11-28	2008-01-23	Orexigen Therapeutics Inc	Metodos para tratar trastornos de ansiedad
US8916195B2 (en)	2006-06-05	2014-12-23	Orexigen Therapeutics, Inc.	Sustained release formulation of naltrexone
ES2600141T3 (es) *	2006-06-19	2017-02-07	Alpharma Pharmaceuticals Llc	Composiciones farmacéuticas
KR101264789B1 (ko) *	2006-06-30	2013-05-15	엘지디스플레이 주식회사	횡전계 방식 액정표시장치용 어레이 기판과 그 제조방법
WO2008011150A1 (en) *	2006-07-20	2008-01-24	Somaxon Pharmaceuticals, Inc.	Methods of improving the pharmacokinetics of doxepin
AU2007319472B2 (en) *	2006-11-09	2013-01-17	Nalpropion Pharmaceuticals Llc	Methods Of Administering Weight Loss Medications
AU2007319471B9 (en)	2006-11-09	2012-10-04	Nalpropion Pharmaceuticals Llc	Layered pharmaceutical formulations comprising an intermediate rapidly dissolving layer
KR20100016445A (ko) *	2007-04-11	2010-02-12	바이오마린 파머수티컬 인크.	테트라하이드로바이오프테린 투여 방법, 관련 조성물 및 측정 방법
DE102007036076A1 (de)	2007-08-01	2009-02-05	Bayer Healthcare Aktiengesellschaft	Dipeptoid-Produgs und ihre Verwendung
WO2009035473A2 (en) *	2007-09-13	2009-03-19	Sanfilippo Louis C	Method of treating binge eating disorder, obesity resulting from binge eating behavior and depressive disorders
CA2725930A1 (en)	2008-05-30	2009-12-30	Orexigen Therapeutics, Inc.	Methods for treating visceral fat conditions
PT2646031T (pt) *	2010-12-03	2017-05-25	Orexigen Therapeutics Inc	Aumento da biodisponibilidade farmacológica numa terapêutica com naltrexona

2011
- 2011-12-02 PT PT118451863T patent/PT2646031T/pt unknown
- 2011-12-02 FI FIEP23209711.3T patent/FI4349369T3/fi active
- 2011-12-02 TW TW100144442A patent/TWI618536B/zh active
- 2011-12-02 SI SI201131967T patent/SI3222280T1/sl unknown
- 2011-12-02 RS RS20210469A patent/RS62149B1/sr unknown
- 2011-12-02 PT PT232097113T patent/PT4349369T/pt unknown
- 2011-12-02 KR KR1020137017317A patent/KR20140035320A/ko not_active Ceased
- 2011-12-02 LT LTEP23209711.3T patent/LT4349369T/lt unknown
- 2011-12-02 PT PT211523147T patent/PT3884947T/pt unknown
- 2011-12-02 RS RS20240196A patent/RS65198B1/sr unknown
- 2011-12-02 US US13/991,137 patent/US20130245056A1/en not_active Abandoned
- 2011-12-02 AR ARP110104512A patent/AR093182A1/es not_active Application Discontinuation
- 2011-12-02 SI SI201131199A patent/SI2646031T1/sl unknown
- 2011-12-02 PL PL11845186T patent/PL2646031T3/pl unknown
- 2011-12-02 EP EP23209711.3A patent/EP4349369B1/en active Active
- 2011-12-02 KR KR1020197014576A patent/KR102105857B1/ko active Active
- 2011-12-02 EP EP21152314.7A patent/EP3884947B1/en active Active
- 2011-12-02 SM SM20250474T patent/SMT202500474T1/it unknown
- 2011-12-02 PL PL17156985T patent/PL3222280T3/pl unknown
- 2011-12-02 EP EP11845186.3A patent/EP2646031B9/en active Active
- 2011-12-02 LT LTEP21152314.7T patent/LT3884947T/lt unknown
- 2011-12-02 MX MX2013006071A patent/MX356801B/es active IP Right Grant
- 2011-12-02 RS RS20170491A patent/RS56014B1/sr unknown
- 2011-12-02 HR HRP20251576TT patent/HRP20251576T1/hr unknown
- 2011-12-02 BR BR112013013390A patent/BR112013013390A2/pt not_active Application Discontinuation
- 2011-12-02 CA CA2819262A patent/CA2819262C/en active Active
- 2011-12-02 RU RU2013127423A patent/RU2640561C2/ru active
- 2011-12-02 FI FIEP21152314.7T patent/FI3884947T3/fi active
- 2011-12-02 PT PT171569858T patent/PT3222280T/pt unknown
- 2011-12-02 HU HUE21152314A patent/HUE065852T2/hu unknown
- 2011-12-02 HR HRP20240115TT patent/HRP20240115T1/hr unknown
- 2011-12-02 LT LTEP17156985.8T patent/LT3222280T/lt unknown
- 2011-12-02 KR KR1020207011510A patent/KR102258043B1/ko active Active
- 2011-12-02 JP JP2013542229A patent/JP6008866B2/ja active Active
- 2011-12-02 CN CN2011800638854A patent/CN103313711A/zh active Pending
- 2011-12-02 AU AU2011336304A patent/AU2011336304B2/en active Active
- 2011-12-02 KR KR1020217015625A patent/KR102391511B1/ko active Active
- 2011-12-02 ES ES11845186.3T patent/ES2625527T3/es active Active
- 2011-12-02 ES ES17156985T patent/ES2866879T3/es active Active
- 2011-12-02 DK DK17156985.8T patent/DK3222280T3/da active
- 2011-12-02 SM SM20170232T patent/SMT201700232T1/it unknown
- 2011-12-02 HU HUE11845186A patent/HUE034393T2/en unknown
- 2011-12-02 HU HUE17156985A patent/HUE053831T2/hu unknown
- 2011-12-02 SM SM20240038T patent/SMT202400038T1/it unknown
- 2011-12-02 PL PL21152314.7T patent/PL3884947T3/pl unknown
- 2011-12-02 DK DK23209711.3T patent/DK4349369T3/da active
- 2011-12-02 SM SM20210227T patent/SMT202100227T1/it unknown
- 2011-12-02 EP EP17156985.8A patent/EP3222280B1/en active Active
- 2011-12-02 DK DK21152314.7T patent/DK3884947T3/da active
- 2011-12-02 WO PCT/US2011/063177 patent/WO2012075459A1/en not_active Ceased
- 2011-12-02 KR KR1020187016354A patent/KR101984500B1/ko active Active
- 2011-12-02 MX MX2017013169A patent/MX384662B/es unknown
- 2011-12-02 LT LTEP11845186.3T patent/LT2646031T/lt unknown
- 2011-12-02 CA CA3239386A patent/CA3239386A1/en active Pending
- 2011-12-02 DK DK11845186.3T patent/DK2646031T3/en active
- 2011-12-02 HR HRP20170734TT patent/HRP20170734T1/hr unknown
- 2011-12-02 SI SI201132102T patent/SI3884947T1/sl unknown
2013
- 2013-05-23 IL IL226504A patent/IL226504B/en active IP Right Grant
- 2013-05-31 CL CL2013001564A patent/CL2013001564A1/es unknown
2016
- 2016-09-12 JP JP2016177391A patent/JP6456890B2/ja active Active
2017
- 2017-05-18 CY CY20171100524T patent/CY1118968T1/el unknown
- 2017-06-26 AU AU2017204309A patent/AU2017204309A1/en not_active Abandoned
2018
- 2018-12-19 JP JP2018237245A patent/JP7025319B2/ja active Active
2019
- 2019-11-21 IL IL270841A patent/IL270841A/en unknown
2020
- 2020-12-21 IL IL279626A patent/IL279626A/en unknown
2021
- 2021-04-19 CY CY20211100340T patent/CY1124331T1/el unknown
- 2021-04-19 HR HRP20210618TT patent/HRP20210618T1/hr unknown
- 2021-12-23 AR ARP210103655A patent/AR124500A2/es unknown
2022
- 2022-02-10 JP JP2022019546A patent/JP2022060331A/ja active Pending
2024
- 2024-03-27 JP JP2024051334A patent/JP2024071605A/ja active Pending

Also Published As

Publication number	Publication date
JP2019056004A (ja)	2019-04-11
RU2017144631A (ru)	2019-02-18
EP2646031A4 (en)	2014-04-23
JP2016210809A (ja)	2016-12-15
CN103313711A (zh)	2013-09-18
PL3884947T3 (pl)	2024-05-06
RU2017144631A3 (lt)	2021-04-13
EP4349369B1 (en)	2025-09-17
FI4349369T3 (fi)	2025-12-17
SI3884947T1 (sl)	2024-06-28
EP4349369A2 (en)	2024-04-10
KR102258043B1 (ko)	2021-05-28
KR102391511B1 (ko)	2022-04-26
CL2013001564A1 (es)	2014-05-02
TWI618536B (zh)	2018-03-21
IL226504B (en)	2021-01-31
JP2024071605A (ja)	2024-05-24
SI2646031T1 (sl)	2017-07-31
WO2012075459A1 (en)	2012-06-07
MX384662B (es)	2025-03-14
PL2646031T3 (pl)	2017-08-31
RS56014B1 (sr)	2017-09-29
SMT201700232T1 (it)	2017-07-18
RU2013127423A (ru)	2015-01-10
ES2866879T3 (es)	2021-10-20
KR20140035320A (ko)	2014-03-21
HUE053831T2 (hu)	2021-07-28
US20130245056A1 (en)	2013-09-19
JP6008866B2 (ja)	2016-10-19
SMT202100227T1 (it)	2021-07-12
CY1124331T1 (el)	2022-07-22
FI3884947T3 (fi)	2024-01-30
BR112013013390A2 (pt)	2016-09-06
CA2819262A1 (en)	2012-06-07
TW201304780A (zh)	2013-02-01
HUE065852T2 (hu)	2024-06-28
MX356801B (es)	2018-06-13
DK2646031T3 (en)	2017-05-22
CA3239386A1 (en)	2012-06-07
KR20210063473A (ko)	2021-06-01
HRP20210618T1 (hr)	2021-09-17
PT4349369T (pt)	2025-12-17
EP3222280A1 (en)	2017-09-27
RS65198B1 (sr)	2024-03-29
SMT202400038T1 (it)	2024-03-13
JP7025319B2 (ja)	2022-02-24
LT4349369T (lt)	2026-01-12
DK3884947T3 (da)	2024-01-22
EP2646031B1 (en)	2017-02-22
EP3222280B1 (en)	2021-01-20
PT3884947T (pt)	2024-02-16
PL3222280T3 (pl)	2021-11-29
HRP20240115T1 (hr)	2024-06-07
ES2625527T3 (es)	2017-07-19
JP2022060331A (ja)	2022-04-14
RU2640561C2 (ru)	2018-01-09
JP2013544290A (ja)	2013-12-12
EP2646031A1 (en)	2013-10-09
PT3222280T (pt)	2021-04-22
KR20180069089A (ko)	2018-06-22
IL279626A (en)	2021-03-01
LT3884947T (lt)	2024-03-12
CY1118968T1 (el)	2018-01-10
IL270841A (en)	2020-01-30
DK4349369T3 (da)	2025-12-22
KR102105857B1 (ko)	2020-05-04
SI3222280T1 (sl)	2021-11-30
AU2011336304A1 (en)	2013-07-11
ES2625527T9 (es)	2018-09-25
KR101984500B1 (ko)	2019-05-31
HRP20251576T1 (hr)	2026-01-30
JP6456890B2 (ja)	2019-01-23
PT2646031T (pt)	2017-05-25
HUE034393T2 (en)	2018-02-28
EP3884947B1 (en)	2023-11-15
EP4349369A3 (en)	2024-05-15
KR20200044158A (ko)	2020-04-28
AR124500A2 (es)	2023-04-05
EP3884947A1 (en)	2021-09-29
KR20190058702A (ko)	2019-05-29
SMT202500474T1 (it)	2026-01-12
CA2819262C (en)	2024-05-28
HRP20170734T1 (hr)	2017-08-11
AU2011336304B2 (en)	2017-03-30
MX2013006071A (es)	2013-10-01
DK3222280T3 (da)	2021-04-19
LT3222280T (lt)	2021-05-10
EP2646031B9 (en)	2018-01-10
RS62149B1 (sr)	2021-08-31
AU2017204309A1 (en)	2017-07-13
AR093182A1 (es)	2015-05-27

Publication	Publication Date	Title
IL279626A (en)	2021-03-01	Increasing the bioavailability of a drug in treatment with naltrexone
GB2479953B (en)	2015-04-29	Drug delivery device
IL226245A0 (en)	2013-07-31	History
IL221007A (en)	2016-06-30	Pharmaceutical combinations for antiviral therapy
ZA201209197B (en)	2016-08-31	Drug delivery device
SG10201700715SA (en)	2017-02-27	Drug delivery device
PL2560624T3 (pl)	2019-01-31	Formulacja terapeutyczna do zmniejszania skutków ubocznych leku
GB201010193D0 (en)	2010-07-21	Medicinal use
EP2643000A4 (en)	2014-05-21	THERAPEUTIC PIPERAZINES
EP2575887A4 (en)	2015-01-14	CONJUGATES OF OPTIMIZED MEDICINES
GB201017597D0 (en)	2010-12-01	Drug detection
ZA201208185B (en)	2014-03-26	Intravaginall drug delivery device
HRP20141173T1 (hr)	2015-01-30	Medikament koji sadrži miramistin
EP2626055A4 (en)	2014-04-16	ACTIVE RELEASE DEVICE
GB201019527D0 (en)	2010-12-29	Redox drug derivatives
GB201006112D0 (en)	2010-05-26	Redox drug derivatives